Literature DB >> 24128902

Rapid 2-stage Norwood I for high-risk hypoplastic left heart syndrome and variants.

Marcello Gomide1, Barbara Furci, Branko Mimic, Kate L Brown, Tain-Yen Hsia, Robert Yates, Martin Kostolny, Marc R de Leval, Victor T Tsang.   

Abstract

OBJECTIVES: Preoperative comorbidities (PCMs) are known risk factors for Norwood stage I (NW1). We tested the hypothesis that short-term bilateral pulmonary arterial banding (bPAB) before NW1 could improve the prognosis of these high-risk patients.
METHODS: From January 2006 to October 2011, 17 high-risk patients with hypoplastic left heart syndrome (defined as having ≥4 of the following PCMs: prolonged mechanical ventilation; older age; sepsis; necrotizing enterocolitis; hepatic, renal, or heart failure; coagulopathy; pulmonary edema; high inotropic requirements; anasarca; weight <2.5 kg; and cardiac arrest) were identified. In addition to conventional treatment of PCMs, they underwent bPAB before NW1. bPAB was undertaken with Silastic slings and secured with ligaclips to a luminal diameter of approximately 3.5 to 4.0 mm. The patency of the ductus arteriosus was maintained with prostaglandin. NW1 was performed using a modified, right Blalock-Taussig shunt at a median interval of 8 days after bPAB. The data from these patients were retrospectively reviewed, and the 30-day mortality and 1-year survival were compared with the hypoplastic left heart syndrome population who underwent primary NW1 with <3 PCMs in the same period.
RESULTS: Of the bPAB patients, 5 (29.4%) died before NW1. All had ≥5 PCMs. Twelve patients (70.6%) survived to undergo NW1. One early death occurred after NW1 (8.3%). The 1-year survival rate for high-risk patients who underwent NW1 was 66.7%. The early mortality and 1-year survival for the 130 patients with <3 PCMs was 10% and 80%, respectively.
CONCLUSIONS: Optimizing the balance between the pulmonary and systemic blood flow with a short period of bPAB and ductal patency can improve the perioperative conditions of high-risk patients before NW1. Those who survived bPAB and underwent NW1 had early mortality and 1-year survival comparable to the standard risk category, despite the severity of their initial condition. A rapid 2-stage NW1 strategy with bPAB and prostaglandin to maintain ductal patency can avoid the risks of suboptimal palliation and vascular injuries associated with hybrid procedures.
Copyright © 2013. Published by Mosby, Inc.

Entities:  

Keywords:  20; HLHS; NW1; Norwood stage I; Q(p)/Q(s); bPAB; bilateral pulmonary arterial banding; hypoplastic left heart syndrome; pulmonary/systemic flow ratio

Mesh:

Substances:

Year:  2013        PMID: 24128902     DOI: 10.1016/j.jtcvs.2013.01.051

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Stage 1 hybrid palliation for hypoplastic left heart syndrome--assessment of contemporary patterns of use: an analysis of The Society of Thoracic Surgeons Congenital Heart Surgery Database.

Authors:  Tara Karamlou; David Overman; Kevin D Hill; Amelia Wallace; Sara K Pasquali; Jeffrey P Jacobs; Marshall L Jacobs; Christopher A Caldarone
Journal:  J Thorac Cardiovasc Surg       Date:  2014-08-14       Impact factor: 5.209

Review 2.  Hypoplastic left heart syndrome: current perspectives.

Authors:  Christopher E Greenleaf; J Miguel Urencio; Jorge D Salazar; Ali Dodge-Khatami
Journal:  Transl Pediatr       Date:  2016-07

Review 3.  Small and borderline left ventricular outflow tract - a perplexing maladie.

Authors:  Manan Desai
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-01-15

Review 4.  Decision-Making for Surgery in the Management of Patients with Univentricular Heart.

Authors:  Ryan Robert Davies; Christian Pizarro
Journal:  Front Pediatr       Date:  2015-07-27       Impact factor: 3.418

5.  Apples to oranges: Making sense of hybrid palliation for hypoplastic left heart syndrome.

Authors:  Travis J Wilder; Christopher A Caldarone
Journal:  JTCVS Open       Date:  2020-10-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.